Medicine

Pricing Climate Impacting Commercial Considerations

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

Leave a Reply

Your email address will not be published. Required fields are marked *